Literature DB >> 1848473

Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features.

G C Toner1, N L Geller, S Y Lin, G J Bosl.   

Abstract

One hundred forty-nine patients with poor risk nonseminomatous germ cell tumors (NSGCT) treated between 1975 and 1988 were studied. Patients were considered poor risk if they had an extragonadal primary site or testicular NSGCT with low predicted probability of achieving a complete response (CR). Primary sites were the testis (99 patients), retroperitoneum (18 patients), and mediastinum (32 patients). Patients with mediastinal NSGCT had lower human chorionic gonadotropin (HCG) (P less than 0.0001) and lactate dehydrogenase (LDH) levels (P less than 0.0001), and more frequent yolk sac elements (P = 0.002). CR rates were 38% for mediastinal, 61% for retroperitoneal, and 38% for testicular primary sites. Mediastinal NSGCT patients more frequently required resection of residual malignancy to attain a CR (6 of 12). Mediastinal NSGCT had the worst event-free survival (P = 0.02). Cox regression analysis identified brain or liver metastases as the most important predictor of event-free survival in poor risk patients. Retroperitoneal NSGCT often have a poor outcome due to advanced presentation, but the likelihood of a CR to therapy can be predicted using criteria applicable to testicular primary tumors. Therefore, not all retroperitoneal NSGCT are poor risk, and retroperitoneal tumors are probably of occult testicular origin. Mediastinal NSGCT have distinct clinical and pathologic features, do not respond as well to chemotherapy, relapse more frequently, and have the worst survival. The likelihood of a CR cannot be predicted using criteria developed for primary testicular tumors, suggesting that mediastinal primary NSGCT is a distinct clinical entity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1848473     DOI: 10.1002/1097-0142(19910415)67:8<2049::aid-cncr2820670807>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  A rare association between malignant mediastinal seminoma and other malignant neoplasms.

Authors:  M Appetecchia; E Pucci
Journal:  J Endocrinol Invest       Date:  2002-04       Impact factor: 4.256

2.  Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience.

Authors:  Alan J Rodney; Nizar M Tannir; Arlene O Siefker-Radtke; Ping Liu; Garrett L Walsh; Randall E Millikan; Stephen G Swisher; Shi-Ming Tu; Lance C Pagliaro
Journal:  Urol Oncol       Date:  2010-10-08       Impact factor: 3.498

3.  Diagnostic and therapeutic challenges in extragonadal yolk sac tumor with hepatoid differentiation: A case report.

Authors:  Vanja Zeremski; Christian Mawrin; Thomas Fischer; Enrico Schalk
Journal:  Mol Clin Oncol       Date:  2016-11-11

4.  Cisplatin-based chemotherapy followed by surgery for malignant nonseminomatous germ cell tumor of mediastinum: one institution's experience.

Authors:  Yukio Nakamura; Akihide Matsumura; Hiroshi Katsura; Masahiro Sakaguchi; Norimasa Ito; Naoto Kitahara; Naoko Ose; Masanori Kitaichi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-07-14

Review 5.  Primary yolk sac tumor of seminal vesicle: a case report and literature review.

Authors:  Xu-Dong Yao; Ya-Ping Hong; Ding-Wei Ye; Chao-Fu Wang
Journal:  World J Surg Oncol       Date:  2012-09-14       Impact factor: 2.754

6.  Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells.

Authors:  M K L Fung; H-W Cheung; M-T Ling; A L M Cheung; Y-C Wong; X Wang
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

7.  Primary malignant mediastinal germ cell tumours: improved prognosis with platinum-based chemotherapy and surgery.

Authors:  W J Childs; P Goldstraw; J E Nicholls; D P Dearnaley; A Horwich
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

8.  First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial.

Authors:  C Bokemeyer; N Schleucher; B Metzner; M Thomas; O Rick; H-J Schmoll; C Kollmannsberger; I Boehlke; L Kanz; J T Hartmann
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

9.  Gastric yolk sac tumor with synchronous liver metastasis: first case report in China.

Authors:  Yanqing Li; Gang Wang; Xiaofei Cheng
Journal:  Transl Cancer Res       Date:  2019-02       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.